Accessory Genes Confer a High Replication Rate to Virulent Feline
Immunodeficiency Virus by Troyer, Ryan M. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Papers in Veterinary and Biomedical Science Veterinary and Biomedical Sciences, Department of 
2013 
Accessory Genes Confer a High Replication Rate to Virulent Feline 
Immunodeficiency Virus 
Ryan M. Troyer 
Colorado State University - Fort Collins 
Jesse Thompson 
University of Nebraska-Lincoln, jthompson12@unl.edu 
John H. Elder 
The Scripps Research Institute 
Sue VandeWoude 
Colorado State University - Fort Collins, sue.vandewoude@colostate.edu 
Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers 
Troyer, Ryan M.; Thompson, Jesse; Elder, John H.; and VandeWoude, Sue, "Accessory Genes Confer a High 
Replication Rate to Virulent Feline Immunodeficiency Virus" (2013). Papers in Veterinary and Biomedical 
Science. 131. 
https://digitalcommons.unl.edu/vetscipapers/131 
This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and 
Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Accessory Genes Confer a High Replication Rate to Virulent Feline
Immunodeficiency Virus
Ryan M. Troyer,a Jesse Thompson,a* John H. Elder,b Sue VandeWoudea
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USAa; Department of Immunology and Microbial Science, The
Scripps Research Institute, La Jolla, California, USAb
Feline immunodeficiency virus (FIV) is a lentivirus that causes AIDS in domestic cats, similar to human immunodeficiency virus
(HIV)/AIDS in humans. The FIV accessory protein Vif abrogates the inhibition of infection by cat APOBEC3 restriction factors.
FIV also encodes a multifunctional OrfA accessory protein that has characteristics similar to HIV Tat, Vpu, Vpr, and Nef. To
examine the role of vif and orfA accessory genes in FIV replication and pathogenicity, we generated chimeras between two FIV
molecular clones with divergent disease potentials: a highly pathogenic isolate that replicates rapidly in vitro and is associated
with significant immunopathology in vivo, FIV-C36 (referred to here as high-virulence FIV [HV-FIV]), and a less-pathogenic
strain, FIV-PPR (referred to here as low-virulence FIV [LV-FIV]). Using PCR-driven overlap extension, we produced viruses in
which vif, orfA, or both genes from virulent HV-FIV replaced equivalent genes in LV-FIV. The generation of these chimeras is
more straightforward in FIV than in primate lentiviruses, since FIV accessory gene open reading frames have very little overlap
with other genes. All three chimeric viruses exhibited increased replication kinetics in vitro compared to the replication kinetics
of LV-FIV. Chimeras containing HV-Vif or Vif/OrfA had replication rates equivalent to those of the virulent HV-FIV parental
virus. Furthermore, small interfering RNA knockdown of feline APOBEC3 genes resulted in equalization of replication rates
between LV-FIV and LV-FIV encoding HV-FIV Vif. These findings demonstrate that Vif-APOBEC interactions play a key role in
controlling the replication and pathogenicity of this immunodeficiency-inducing virus in its native host species and that acces-
sory genes act as mediators of lentiviral strain-specific virulence.
Feline immunodeficiency virus (FIV) is a lentivirus closely re-lated to human immunodeficiency virus (HIV) and simian
immunodeficiency virus (SIV) that infects numerous feline spe-
cies (1–3). FIV infection of the domestic cat is an importantmodel
for HIV, as it is the only nonprimate lentivirus that causes an
AIDS-like syndrome in its natural host. Feline and human AIDS
are both characterized by recrudescence of high levels of circulat-
ing virus, progressive loss of CD4 T-lymphocytes, neutropenia,
weight loss, gingivitis, neurological impairment, and opportunis-
tic infections (4–8). FIV is also similar to HIV in its cellular tro-
pism (9, 10), genomic organization (11), coding of regulatory ac-
cessory proteins (12), and utilization of a two-receptor cellular
entrymechanism (13–16). These similarities and awell-developed
experimental cat infectionmodel (9, 12, 17, 18) facilitate the study
of lentiviral pathogenesis in a native host species, as well as the
development of preventative and therapeutic strategies.
HIV disease progression to AIDS varies dramatically between
infected individuals, and understanding the basis for this variabil-
ity is critical to combating the disease.While host genetics, immu-
nity, and underlying medical conditions account for a portion of
this variability (19–21), the pathogenicity of the infecting virus has
also been associated with disease progression (22–29). Further-
more, HIV replication capacity and pathogenicity can vary be-
tween viral subtypes (30–35) or between strains within the same
subtype (36–39). The basis for this variability in disease potential
is still poorly understood.
Similar toHIV, FIV exhibits structural and functional diversity
that dictates the nature and extent of its pathogenicity in vivo.
There are multiple genetic subtypes of FIV (40–42), and strains
within these subtypes exhibit various degrees of pathogenicity (5,
43–46). One subtype C isolate causes particularly high disease
incidence and severity, with 60% of young cats developing severe
acute immunodeficiency syndrome within 12 to 18 weeks follow-
ing experimental infection (5).We previously characterized amo-
lecular clone, FIV-C36 (referred to hereinafter as high-virulence
FIV [HV-FIV]), that recapitulates the highly pathogenic pheno-
type of the parental virus (17). In contrast, the subtype A molec-
ular clone FIV-PPR (referred to hereinafter as low-virulence FIV
[LV-FIV]) exhibits relatively low pathogenicity in experimentally
infected cats and replicates to significantly lower levels than HV-
FIV in vitro and in vivo (46, 47). To understand the basis for this
difference in pathogenicity, we previously produced chimeras be-
tween these HV- and LV-FIV strains and compared their replica-
tion in vitro and pathogenicity in vivo. FIV-PCenv, a chimera con-
taining the 3= half of HV-FIV, including vif, orfA, rev1, and env, on
the LV-FIVbackgrounddemonstrated intermediate, although de-
layed, viral loads and hematological pathology during primary
infection of cats (47). Passage of FIV-PCenv from infected cats
into naive cats resulted in higher viral loads, similar to those ob-
served during parental HV-FIV infections, which are not delayed
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compared to the infection kinetics of parental constructs (48).
Thus, the results from experiments with subtype A/C chimeric
FIV-PCenv suggest that elements from the 3= half of the genome,
including the accessory genes vif and orfA, contribute to the
heightened virulence observed during infections with theHV-FIV
strain.
The FIV vif gene is necessary for virus replication in vitro (49–
51) and in vivo (52, 53). Lentiviral Vif promotes viral replication
by binding host APOBEC3 (A3) cytidine deaminases and induc-
ing their degradation via the proteasome (54–57). In the absence
of functional Vif, A3 proteins are incorporated into assembling
virus particles (55, 58, 59). After virions carrying A3 protein infect
a new cell, A3 can deaminate cytidines in lentiviral minus-strand
DNA, resulting in G-to-A hypermutation in the provirus (58, 60–
62). Additionally, A3 proteins also appear to reduce the accumu-
lation of reverse transcription products and inhibit lentiviral rep-
lication by a deamination-independent mechanism (63–66).
Feline species encode four A3 genes, including three very similar
A3Z2 genes (a to c) and an A3Z3 gene (67–69). These genes were
formerly known asA3C (c, a, and b) andA3H, respectively (70). In
addition to these four one-domain proteins, a two-domain
A3Z2-Z3 protein (formerly A3CH) is produced by alternative
splicing (68, 71). The replication of FIV lacking Vif or wild-type
HIV is strongly restricted by feline A3Z3 and A3Z2-Z3, while the
A3Z2 proteins have no effect (68, 69, 71, 72). The expression of
FIV Vif reverses feline A3Z3- and A3Z2-Z3-mediated lentiviral
restriction (68, 71, 72).
FIV does not encode distinct regulatory proteins that are di-
rectly comparable toHIVTat, Vpr, Vpu, orNef.However, the FIV
genome does include a multifunctional 77-amino-acid nonstruc-
tural viral protein expressed from the orfA gene, located between
vif and env. OrfA is necessary for efficient FIV replication in lym-
phocytes in vitro and in vivo (52, 73–76). Multiple potential func-
tions have been ascribed to OrfA, including transactivation of vi-
ral protein expression (77), effects on virion formation and
infectivity (73), cell cycle arrest (78), effects on cellular gene ex-
pression (79), and downregulation of cell surface expression of the
primary FIV receptor, CD134 (80).
Our previous studies implicating 3= viral genomic elements in
the rapid-growth kinetics and heightened virulence of HV-FIV
relative to the growth kinetics and virulence of LV-FIV (47, 48) led
us to hypothesize that the FIV regulatory accessory genes vif
and/or orfAmay be responsible for this difference in viral replica-
tion capacity.Here, we describe the construction of three chimeric
viruses in which LV-FIV vif, orfA, or both were replaced with
HV-FIV versions of these genes. Comparison of the growth kinet-
ics of these constructs in multiple ex vivo contexts and in the pres-
ence or absence of feline A3 suggests that (i) accessory genes con-
vey different capacities for in vitro replication and (ii) Vif-A3
interactions are largely responsible for the increased replication
capacity ofHV-FIV. Thus, this study suggests that lentiviral acces-
sory proteins may play a critical role in determining the differ-
ences in viral replication capacity and pathogenicity between
strains.
MATERIALS AND METHODS
Animals. Blood donor cats were housed in a specific-pathogen-free
AAALAC International-accredited animal facility at Colorado State Uni-
versity. All procedures were approved by the CSU Institutional Animal
Care and Use Committee prior to initiation.
Generation of FIV chimeric constructs. FIV chimeric clones were
produced in which vif, orfA, or vif/orfA from high-virulence FIV (HV-
FIV) (FIV-C36 [17]) replaced these genes in low-virulence FIV (LV-FIV)
(FIV-PPR [81]). Chimeric virus construction was performed using a
modified PCR-driven overlap extension technique (82). This technique
allowed us to insert HV-FIV vif, orfA, or vif/orfA into the LV-FIV genome
with highly specific gene junctions that were not dependent on restriction
enzyme site locations. We used plasmids containing full-length LV-FIV
and HV-FIV parental constructs as the PCR templates to generate three
overlapping fragments: AB (LV), CD (HV), and EF (LV). The primers for
these reactions were designed to ensure accurate junctions between pa-
rental constructs. All primer sequences are listed in Table S1 in the sup-
plemental material. Primers A and F, specific for pLV-FIV, were used for
the generation of all chimeras. Primers B.1 and E.1 were used in the con-
struction of FIV-HVvif, while primers B.2 and E.2 were used for FIV-
HVorfA. Based on the 5=-to-3= arrangement of vif and orfA on the FIV
genome, primers B.1, C.1, D.2, and E.2 were used for the construction of
FIV-HVvif/orfA. PCRs were conducted with Platinum Pfx DNA high-
fidelity polymerase (Life Technologies, Carlsbad, CA) using the following
cycling conditions: 30 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 1
min. Productswere separated on an agarose gel, stainedwith crystal violet,
and extracted using theQIAquick gel extraction and purification kit (Qia-
gen, Valencia, CA). After the self-primed overlapping reaction between
fragments AB, CD, and EF, we amplified the full-length chimeric AF
product with primers A and F to generate sufficient amounts for agarose
gel extraction and ligation into pLV-HIV. The self-primed and AF ampli-
fication cycling conditions were as follows: 30 cycles of 94°C for 15 s, 58°C
for 30 s, and 68°C for 2 min.
The chimeric AF fragments were digested with restriction endonu-
cleases EcoRV, Bsu36I, and BclI and ligated into pLV-FIV using T4 DNA
ligase according to the manufacturer’s specifications (New England Bio-
Labs, Ipswich, MA). All chimeric clones were transformed in MAX Effi-
ciency Stbl2 competent Escherichia coli (Life Technologies) and grown at
30°C in order to avoid instability and recombination of lentiviral se-
quences. All constructs were validated by restriction enzyme analysis and
PCR using primer sets AD, CD, and CF. Clones were directly sequenced
by Laragen, Inc. (LosAngeles, CA), and the sequenceswere analyzed using
Sequencher software (Gene Codes Corporation, Ann Arbor,MI) to verify
the LV-/HV-FIV junctions and the reestablishment of restriction sites.
Cells and culture conditions.Crandell feline kidney cells (CrFK) (83),
Mya-1 feline T-lymphoblastoid cells (84), and human 293T cells were
obtained from the American Type Culture Collection (ATCC, Manassas,
VA). CrFK-CD134 cells, also known as GFox cells, are CrFK cells stably
transfected with the FIV primary binding receptor CD134 (14). CrFK and
CrFK-CD134 cells were grown at 37°C in 5%CO2 inDulbecco’smodified
Eagle’s medium (DMEM) with GlutaMAX-1, 1 g/liter D-glucose, and 110
mg/liter sodium pyruvate (Life Technologies, Carlsbad, CA) supple-
mentedwith 10% fetal bovine serum (FBS;HyClone, Logan, UT), 0.075%
sodium bicarbonate, 0.1 mM minimal essential medium (MEM) nones-
sential amino acids, and 1 penicillin-streptomycin (10,000 U/liter pen-
icillin and 10,000 g/liter streptomycin; Life Technologies). We purified
primary feline peripheral blood mononuclear cells (PBMC) from blood
samples obtained from specific-pathogen-free adult cats in a breeding
colony at Colorado State University. This procedure was approved by the
CSU Institutional Animal Care and Use Committee. PBMCwere isolated
on a Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) gradient and
washed with phosphate-buffered saline (PBS). Primary feline PBMC, as
well asMya-1 cells, were grown at 37°C in 5%CO2 in RPMI 1640medium
with GlutaMAX-1 (Life Technologies) supplemented with the following:
20% FBS, 9 g/liter D-glucose (Sigma-Aldrich), 1 penicillin-streptomy-
cin, 0.075% sodiumbicarbonate, 0.1mMMEMnonessential amino acids,
1 mM sodium pyruvate, 0.055 mM 2-mercaptoethanol (Life Technolo-
gies), and 10 ng/ml human recombinant interleukin-2 (Millipore, Te-
mecula, CA).Human 293T cells were grown at 37°C in 5%CO2 inDMEM
medium with 4.5 g/liter D-glucose and 110 mg/liter sodium pyruvate,
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supplemented with the following: 2 GlutaMAX-1 (Life Technologies),
10% FBS, and 1 penicillin-streptomycin.
Generation and titration of viral stocks. Plasmids containing full-
length FIV genomes were transfected into CrFK cells using Lipofectamine
2000 as described by themanufacturer (Life Technologies, Carlsbad, CA).
Briefly, 1  106 CrFK cells were plated in 6-cm dishes in antibiotic-free
mediumand incubated for 24 h. Cells were transfected by adding 6g FIV
plasmid and 15l Lipofectamine 2000 diluted inOpti-MEM I (Life Tech-
nologies). At 15 h posttransfection, the medium was removed and re-
placed with antibiotic-containing medium. Cell supernatants were col-
lected at 48 h posttransfection, centrifuged at 900  g for 10 min to
remove cells and cellular debris, and tested for the presence of FIV p26
capsid by enzyme-linked immunosorbent assay (ELISA) (85). One milli-
liter of each CrFK supernatant was then used to infect 4.4  107 Mya-1
cells in 44 ml medium, and the level of FIV p26 in the supernatant was
monitored daily. On day 8, all infected cultures had reached peak p26
levels, so supernatants were collected and centrifuged at 900  g for 10
min to remove cells, and aliquots were frozen at80°C. The 50% tissue
culture infectious dose (TCID50) of viral stocks was then determined by
titration onMya-1 cells. Viral stocks were diluted in five replicate 10-fold
dilution series and added to 2 105Mya-1 cells per well in 96-well plates.
FIV reverse transcriptase (RT) activity in day 14 supernatant was deter-
mined as previously described (86, 87), and the Spearman-Karbermethod
was used to calculate the TCID50.
Assessment of in vitro infection kinetics. FIV replication kinetics
were assessed inMya-1 T cells and cat PBMC.Mya-1 T cells at a density of
1 106 cells/ml mediumwere infected with FIV at a multiplicity of infec-
tion (MOI) of 0.001 TCID50 per cell. Freshly isolated PBMC from four
pathogen-free domestic cats were pooled and stimulated in culture at 2
106 cells/ml with 5 g/ml concanavalin A (ConA; Sigma-Aldrich, St.
Louis, MO). After 3 days of ConA treatment, PBMC were readjusted to
2 106 cells/ml in fresh medium without ConA and infected with FIV at
an MOI of 0.001. FIV replication was assessed in cell culture supernatant
bymeasuring FIV p26 capsid antigen using a previously described capture
ELISA (85) or by determining FIV RT activity as previously described (86,
87). For quantitation of FIV DNA load, cells were pelleted by centrifuga-
tion at 580 g for 5min, andDNAwas extracted using the DNeasy blood
and tissue kit (Qiagen, Valencia, CA). The FIVDNA load in cellular DNA
was then determined by quantitative PCR (qPCR) as previously described
(48) using primer and probe sets specific for FIV clade A and FIV clade C
(45).
Measurement of CD134 expression. FIV-infected and uninfected
PBMC (5  105 cells) were collected by centrifugation at 580  g for 5
min, resuspended in 150 l cold flow buffer (phosphate-buffered saline
with 5% fetal bovine serum), and blocked with 30 l goat serum (MP
Biomedicals, Solon, OH) for 30 min at 4°C. Cells were washed twice with
flow buffer, resuspended in 100 l flow buffer, and incubated with 0.5 l
CD4-fluorescein isothiocyanate (FITC) antibody (clone 3-4F4; Southern
Biotech, Birmingham, AL) and 5 l CD134-Alexa Fluor 647 antibody
(clone 7D6; AbD Serotec, Raleigh, NC) for 30 min at 4°C. Cells were
washed three timeswith flowbuffer and resuspended in 170l flow buffer
containing 0.3 g/ml propidium iodide (PI; Sigma-Aldrich, St. Louis,
MO). Flow cytometry was performed immediately on a CyAn ADP flow
cytometer (Beckman Coulter, Brea, CA). Isotype controls produced by
incubating PBMCwithmouse IgG1 (clone 15H6; Southern Biotech) con-
jugated to FITC or Alexa Fluor 647 were used to set gates at less than 1%
positive cells for each isotype control. The percentages of cells staining
positive for PI (dead or dying cells) were compared between viral infec-
tions, and PI-positive cells were excluded from the CD134 analyses. The
mean fluorescence intensities (MFI) of CD134 on CD4 cells of FIV-
infected cultures were compared to the MFI on uninfected PBMC.
Viral sequencing. FIV RNA was purified from 140 l of FIV-infected
Mya-1 supernatant using the QIAamp viral RNAminikit (Qiagen, Valen-
cia, CA). Viral RNA was converted to cDNA using random primers and
Superscript II RT (Life Technologies, Carlsbad, CA) according to the
manufacturer’s instructions. The FIV vif/orfA region was amplified by
PCR with primers Vif/Orf-F1 and Vif/Orf-R1 (see Table S1 in the supple-
mental material) using TaqDNAPolymerase (Life Technologies) accord-
ing to the manufacturer’s instructions, using the following cycling condi-
tions: 35 cycles of 94°C for 45 s, 55°C for 30 s, 72°C for 90 s. The integrase
portion of FIV pol was amplified with primers Int-F2 and Int-R2 (see
Table S1) using identical conditions except that a PCR annealing temper-
ature of 52°C was used. DNA sequencing was performed by the Colorado
StateUniversity Proteomics Facility. Chromatograms and sequences were
analyzed using Sequencher software (Gene Codes Corporation, Ann Ar-
bor, MI).
siRNAknockdown experiments.For specific depletion of felineA3Z3
and A3Z2-Z3 expression, we designed a small interfering RNA (siRNA)
(Dharmacon, Lafayette, CO) which targets feline A3Z3 (see Table S1 in
the supplemental material). To differentiate between the effects of A3Z3
knockdown and nonspecific effects of RNA transfection, we also utilized
siGENOME control nontargeting siRNA number 3 fromDharmacon as a
negative control. A3Z3 knockdown for virus production was conducted
in CrFK cells by plating 1 106 cells in 6-cm dishes. After 6 h of incuba-
tion, cells were transfected with siRNA at a 50 nM concentration using 2
l/ml Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA) ac-
cording to the manufacturer’s instructions. At 24 h after siRNA transfec-
tion, themediumwas removed, cells were washed with PBS, and each FIV
plasmid (2 g) was transfected using 15 l Lipofectamine 2000 as de-
scribed by the manufacturer (Life Technologies, Carlsbad, CA). At 15 h
after FIV plasmid transfection, the medium was removed, cells were
washed with PBS, and fresh medium was added. Cell supernatants were
collected at 48 h after FIV plasmid transfection, centrifuged at 900 g for
10min to remove cells and cellular debris, aliquoted, and frozen at80°C.
Additional virus stocks were produced in control siRNA-transfected cells,
which express A3Z3 normally, by identical procedures.
To accurately compare the levels of FIV p26 capsid between virus
stocks, we performed FIV p26 ELISA on triplicate 2-fold dilution series of
each virus stock. Linear plots of FIV p26 (at an optical density of 450 nm
[OD450]) versus dilutions of virus stock were used to determine the
amount of each virus stock equivalent to 0.2 OD450, and subsequent in-
fections were initiated with this amount of each virus, containing equal
FIV p26. To compare FIV replication in the presence or absence of A3Z3,
1.8 105 CrFK-CD134 cells in 12-well plates were transfected with con-
trol siRNA or anti-A3Z3 siRNA as described above and, 24 h later, in-
fected with FIV stocks produced in A3Z3-expressing cells or A3Z3-de-
pleted cells, respectively. FIV replicationwas quantified bymeasuring FIV
p26 levels in cell culture supernatants on days 2, 4, and 6 following infec-
tion.
Detection of feline APOBEC3 gene expression by qPCR. RNA was
extracted from cells using TRIzol reagent (Life Technologies, Carlsbad,
CA) according to the manufacturer’s instructions. Any remaining DNA
was then eliminated by treatment with DNase I, amplification grade (Life
Technologies), using 2 U in a 50-l volume. RNA preparations were fur-
ther purified using the RNeasy minikit (Qiagen, Valencia, CA) RNA
cleanup protocol and quantified using an ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE). Cellular RNA was con-
verted to cDNA according to the manufacturer’s instructions for Super-
script II (Life Technologies), using random hexamer primers.
Feline APOBEC3 (A3) cDNA was quantified by qPCR using primers
specific for A3Z2, A3Z3, and A3Z2-Z3 (see Table S1 in the supplemental
material). The A3Z2 primers detect the expression of all three feline A3Z2
isoforms (A3Z2a, A3Z2b, and A3Z2c) collectively. The A3Z2-Z3 primers
detect the expression of all A3Z2-Z3 variants (A3Z2b-Z3, A3Z2c-Z3, and
splice variants). The reaction mixtures were prepared with SsoFast
EvaGreen supermix (Bio-Rad, Hercules, CA) and 400 nM primers and
were run on a CFX96 real-time PCR detection system (Bio-Rad) using the
following conditions: 95°C for 30 s, 40 cycles of 95°C for 5 s, and 60°C for
10 s, followed by a 65-to-95°Cmelt curve analysis. An A3Z2b-Z3 plasmid
standard curve was used to determine copy number for all three A3
Troyer et al.
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qPCRs. Since the A3Z2 and A3Z3 primers also detect A3Z2-Z3 expres-
sion, we subtracted the A3Z2-Z3 copy number from the A3Z2 and A3Z3
copy numbers for each sample. The validity of this subtractive method is
supported by the use of a single A3Z2b-Z3 plasmid standard curve for all
A3 qPCRs and qPCR efficiencies that were consistently in the 95-to-100%
range for these assays. A3 mRNA copy numbers were normalized to glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) expression using a
previously described qPCR assay for feline GAPDH (88) with a feline-
GAPDH-encoding plasmid standard curve. All primer pairs span exon
junctions, and melt curves run on all qPCRs showed single-amplification
products, demonstrating target specificity for all assays.
Statistical analyses. For all comparisons of FIV replication over time,
we determined whether the level of FIV differed significantly between the
virus strains over time by performing repeated-measures analysis of vari-
ance (ANOVA) on each pairwise combination of viruses and examining
the time by virus interaction. CD134 expression over time was similarly
assessed with repeated-measures ANOVA on each pairwise combination
of viruses. The replication of FIV in the siRNA knockdown experiments
was compared by repeated-measures ANOVA with Bonferroni posttests.
For all experiments, a P value of0.05 was considered the threshold for
significance.
RESULTS
Generation of chimeric viruses. Chimeric FIV constructs were
produced in which vif, orfA, or both genes from high-virulence
FIV (HV-FIV) (FIV-C36) replaced these genes in the low-viru-
lence FIV (LV-FIV) (FIV-PPR) viral genome, generating FIV-
HVvif, FIV-HVorfA, and FIV-HVvif/orfA (Fig. 1; for details of
chimera junctions, see Fig. S1 in the supplemental material). Se-
quencing of each clone verified each chimeric construct (see Fig.
S1) with intact insertion of HV-FIV vif and vif/orfA into the LV-
FIV genome. Two conservative amino acid changes were identi-
fied near the carboxy terminus of integrase (IN). Infectious FIV
was recovered for comparative studies by transfecting CrFK cells
with FIV-HVvif, FIV-HVorfA, and FIV-HVvif/orfA chimeric
plasmids, as well as HV-FIV and LV-FIV parental plasmids. Cell
supernatants removed at 48 h posttransfection all had levels of FIV
p26 capsid that were detectable by ELISA (data not shown); each
supernatant was then used to generate amplified virus stocks by
growth in Mya-1 T cells. Supernatants were harvested at day 8
when maximum p26 levels were detected. We determined the
50% tissue culture infectious dose (TCID50) by infecting Mya-1
cells with serial dilutions of viral stocks andmeasuring RT activity
at 14 days postinfection.
HV-FIV vif and orfA confer increased replication capacity to
LV-HIV inMya-1 T cells.We compared the replication of vif and
orfA chimeric viruses to that of parental strains by infectingMya-1
T cells with equal TCID50s of each virus and monitoring FIV p26
capsid in cell culture supernatants by ELISA for 15 days (Fig. 2). As
expected, HV-FIV replicated with dramatically increased kinetics
compared to the replication kinetics of LV-FIV. FIV-HVorfA
demonstrated replication kinetics intermediate to those of paren-
tal strains, indicating that HV-FIV orfA provides a significant rep-
lication advantage over LV-FIV orfA. BothHV-FIV vif-containing
chimeric viruses (FIV-HVvif and FIV-HVvif/orfA) had strongly
increased replication kinetics compared to the replication kinetics
of LV-FIV. In fact, HV-FIV vif chimeric virus replication ap-
proached that of the virulent FIV parental strain. This result
indicates that both OrfA and Vif contribute to the inherent
differences noted for the in vitro replication capacities of HV-
FIV and LV-FIV.
Multicycle replication of chimeric viruses has the potential to
result in the selection of adaptive mutations within or surround-
ing the chimeric region. We have previously observed this phe-
nomenon in the integrase-encoding portion of pol in the FIV-
PCenv chimera (48). To determine whether any mutations were
selected for in our chimeric virus production and subsequent rep-
lication in Mya-1 cells, we sequenced viral RNA from the day 15
supernatants of Mya-1 cell infections, whose replication kinetics
are shown in Figure 2.We evaluated vif, orfA, andflanking regions,
FIG 1 FIV accessory gene chimeras. HV-FIV orfA and vif genes were ex-
changed with those of LV-FIV using PCR-driven overlap extension. Genome
schematics for SIVmac and HIV illustrate that analogous chimeras cannot be
developed for primate lentiviruses because their accessory gene open reading
frames overlap extensively with other genes.
FIG 2 Chimeric FIV replication in Mya-1 T cells. Mya-1 cells were infected
with FIV chimeric and parental viruses at an MOI of 0.001, and cell culture
supernatants were assayed by FIVp26 capsid antigen ELISA (n 3). Error bars
represent standard errors of the means. In this experiment, the levels of FIV
differed significantly over time (P  0.05) for each pair of viruses, with the
exception of FIV-HVvif versus FIV-HVvif/orfA, which did not differ signifi-
cantly (P 0.05).
FIV Replication Rate Is Accessory Gene Dependent
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including the entire integrase portion of pol, for all five viruses and
found that the consensus sequences were identical to the original
plasmid clone sequences (data not shown). While lentiviral infec-
tions inherently result in the sporadic occurrence of mutations,
these data indicate that virus production during 15 days of repli-
cation in Mya-1 T cells was consistent with input virus and that
outgrowth was not a result of in vitro selection.
In order to confirm these results using viral detection assays
other than p26 ELISA, we repeated the Mya-1 T-cell infections
and measured RT activity in the supernatants and FIV proviral
loads by qPCR. FIV growth kinetics as detected byRT activity (Fig.
3A) were similar to those detected by FIV p26 ELISA (Fig. 2). RT
activity recapitulated earlier observations; namely, FIV-HVorfA
replicated with increased kinetics compared to the replication
of parental LV-FIV, while the HV-FIV vif-containing viruses
(FIV-HVvif and FIV-HVvif/orfA) had replication kinetics that
approached the replication of parental HV-FIV (Fig. 3A). The
proviral DNA loads also indicated that all three chimeric viruses
(FIV-HVvif, FIV-HVvif/orfA, and FIV-HVorfA) had greater FIV
DNA loads than LV-FIV (Fig. 3B). Thus, three different method-
ologies for assessing viral replication confirmed that HV-FIV vif-
and orfA-expressing chimeric viruses had increased replication
capacities compared to the replication of the parental LV-FIV.
vif and orfA chimeric viruses have increased replication ca-
pacities in cat PBMC ex vivo. As a more-relevant biological
model, we next sought to determine whether HV-FIV vif and orfA
could also confer a replication advantage to LV-FIV in cat PBMC
ex vivo. We infected pathogen-free cat PBMC with equal TCID50s
of each of the five viruses and monitored FIV p26 capsid in cell
culture supernatants by ELISA for 15 days (Fig. 4A). The differ-
ences in themagnitude and kinetics of viral growthwere similar to
the observations inMya-1 T cells. FIV-HVorfA had increased rep-
lication kinetics compared to the replication of LV-FIV; HV-FIV
vif-containing chimeric viruses (FIV-HVvif and FIV-HVvif/orfA)
had significantly increased growth kinetics compared to the
growth of LV-FIV and FIV-HVorfA (P  0.05). Furthermore,
HV-FIV vif chimeric viruses actually trended toward increased
replication relative to that of parental HV-FIV. Thus, FIV growth
in feline PBMC supports the observations in Mya-1 T cells—HV-
FIV orfA confers a moderate, yet significant replication advantage
to LV-FIV, while HV-FIV vif confers a strong replication advan-
tage in primary cells isolated from outbred animals.
FIG 3 Reverse transcriptase activities and FIV DNA loads in chimeric FIV-infected Mya-1 T cells. Mya-1 cells were infected with FIV chimeric and parental
viruses at anMOI of 0.001.We assayed the cell culture supernatant for FIV RT activity and used cellular DNA to determine FIVDNA load by qPCR. (A) For FIV
RT activities, the levels differed significantly over time (P 0.05) for each pair of viruses, with the exception of FIV-HVvif versus FIV-HVvif/orfA, which did not
differ significantly (P 0.05). (B) For FIVDNA loads, theHV-FIV loadwas significantly greater than those of all other viruses (P 0.05), and the three chimeric
viruses (FIV-HVvif, FIV-HVvif/orfA, and FIV-HVorfA) had significantly higher FIVDNA loads than LV-FIV (P 0.05). The three chimeric viruses did not vary
significantly from each other in FIV DNA load (P 0.05). All experiments were performed in triplicate, and error bars represent standard errors of the means.
FIG 4 Replication of chimeric FIV and CD134 expression in cat PBMC ex vivo. (A) PBMC were infected with FIV chimeric and parental viruses at an MOI of
0.001, and FIV replicationwas assayed by FIVp26 capsid ELISA. FIVp26 capsid pairwise comparisons betweenHV-FIV, FIV-HVvif, and FIV-HVvif/orfA yielded
no significant difference in the levels of FIV over time (P 0.05). All other virus pairwise comparisons showed significant differences (P 0.05). (B) PBMCwere
collected on days 4, 7, 10, and 14 (n 3) for flow cytometric measurement of CD134mean fluorescence intensity (MFI) on infected CD4 T cells relative to that
on uninfected CD4 T cells. For CD134 expression, all pairwise comparisons showed significant differences in CD134 expression over time (P 0.05). CD134
expression was associated with the quantity of productive virus rather than the strain identity of the orfA gene. Experiments were conducted in triplicate, and
error bars represent standard errors of the means.
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CD134 expression in FIV chimeric virus-infected PBMC.
FIV infection of cells results in downregulation of the FIV primary
binding receptor CD134 (80, 89), which is analogous to the ability
of HIV to downregulate the CD4 receptor (90). Recently, FIV
OrfA was found to be sufficient to mediate CD134 downregula-
tion (80). We measured CD134 expression on CD4 T cells in
infected PBMC cultures to investigate whether variations in orfA
genes affected the extent of CD134 downregulation. The expres-
sion of CD134 in FIV-infected cultures relative to its expression in
uninfected PBMC is shown in Figure 4B. Comparison of CD134
downregulation (Fig. 4B) and FIV replication kinetics (Fig. 4A)
revealed an inverse relationship; cultures infected with the more-
rapidly replicating FIV-HVvif and FIV-HVvif/orfA had decreased
CD134 expression compared with the CD134 expression in cul-
tures infected with more-slowly replicating viruses, such as LV-
FIV. Propidium iodide staining did not reveal significant differ-
ences in viral cytopathicity at any time point (data not shown).
The degree of CD134 downregulation is apparently independent
of the identity of the orfA gene, i.e., LV-FIV orfA-containing vi-
ruses had both the lowest (FIV-HVvif) and the highest (LV-FIV)
CD134 expression. To our knowledge, this is the first study to
demonstrate that FIV can induce downregulation of CD134 in cat
CD4 T cells ex vivo.
Thus, CD134 downregulation correlates more strongly with
the quantity or rapidity of productive virus than with the strain
identity of the orfA gene. As noted from the results shown in Fig-
ures 2, 3, and 4A, orfA may influence replication capacity and,
thus, result in differences in the degree of CD134 cell surface ex-
pression on PBMC.
APOBEC3 mRNA expression in feline cells. The primary
function of lentiviral Vif is to bind and induce the degradation of
cognate host APOBEC3 (A3) proteins, thereby protecting the vi-
rus from the antiviral effects of these proteins (91, 92). Since Vif-
based differences in replication may involve interactions with A3
proteins, we quantified the levels of A3 mRNA expression in the
feline cell types used in this study to determine whether these cells
express A3 mRNA and whether cell type-specific differences in
expression exist. We determined the A3 mRNA expression of
CrFK cells, Mya-1 cells, and cat PBMC by quantitative real-time
PCR and found that all three cell types expressed A3Z2, A3Z3, and
A3Z2-Z3 mRNAs (Fig. 5). Total A3Z2 (including all three A3Z2
homologs) mRNA expression was highest, followed by A3Z3
mRNA expression. The expression of A3Z2-Z3 double-domain
mRNAs was very low relative to the expression of single-domain
A3Z2 and A3Z3 mRNAs. For instance, PBMC had 300-fold
higher levels of A3Z3 than of A3Z2-Z3 mRNA. Since feline A3Z3
and several A3Z2-Z3 variant proteins can inhibit FIV (in the ab-
sence of Vif), while the three A3Z2 homologs do not inhibit FIV
(68, 71), the low abundance of A3Z2-Z3 mRNA compared to the
abundance of A3Z3 suggests that A3Z3 is the major antilentiviral
A3 protein present in domestic cats. Notably, the expression level
of A3Z3 in cat PBMCandMya-1 cells is very similar to the levels of
APOBEC3G and APOBEC3F reported for macaque PBMC and
CD4 T cells (93), suggesting that important antilentiviral A3s in
other species are expressed at comparable levels. Comparing the
three feline cell types examined, CrFK cells had lower A3Z3
mRNA levels than PBMC andMya-1, whileMya-1 cells had lower
A3Z2-Z3 mRNA levels than PBMC and CrFK cells. However, all
three cell types expressed appreciable levels of A3 mRNAs and,
therefore, have the potential to exhibit A3-mediated viral restric-
tion.
Vif-specific replication is dependent on felineAPOBEC3.We
hypothesized that the difference in the replication capacity of FIV-
HVvif relative to that of the parental LV-FIV would be dependent
on the action of feline APOBEC3 (A3) proteins. To assess this
hypothesis, we sought to compare the replication of HV-FIV, LV-
FIV, and FIV-HVvif in cells depleted of feline A3 proteins. Since
all of the anti-FIV feline A3 proteins contain a Z3 domain, we
designed an siRNA targeting A3Z3 to allow us to specifically de-
plete anti-FIV A3 from cells. Transfection of CrFK cells with anti-
A3Z3 siRNA reduced A3Z3 and A3Z2-Z3 mRNA expression by
85% for 7 days, while the expression of A3Z2 was unaffected
(Fig. 6).
To compare FIV replication under conditions of transient
siRNA transfection, we designed a short-course infection experi-
ment utilizing highly transfectable CrFK cells that have been en-
gineered to express the FIV receptor, CD134, allowing multiple
rounds of viral replication and production of progeny virions
(GFox cells [14]). Because A3 exerts antiviral effects via incorpo-
ration into a lentiviral virion from a virus producer cell, thereby
resulting in subsequent viral inhibition upon infection of a naive
target cell, we depleted A3 from both producer and target cells
using siRNA to assess FIV replication in the near-complete ab-
sence of A3 as follows: (i) two parental strains of FIV and FIV-
HVvif were produced in A3-depleted CrFK, and (ii) viral inocula
were normalized by gag equivalents and used in equal amounts
(iii) to infect CrFK-CD134 cells depleted of A3 following siRNA
transfection. Concurrently, to assess FIV replication under condi-
tions of normal A3 expression in both producer and target cells,
CrFK-CD134 cells expressingA3were infectedwith FIVproduced
in CrFK cells expressing A3. Since LV-FIV and FIV-HVvif only
differ in vif, any difference in replication between these viruses
would be attributable to the action of HV-FIV Vif versus LV-FIV
Vif. In CrFK-CD134 cells expressing normal levels of A3Z3 and
A3Z2-Z3, we found that FIV-HVvif was detected in significantly
higher levels in the supernatant than LV-FIV (Fig. 7A), consistent
with the results of replication experiments in Mya-1 T cells and
domestic cat PBMC (Fig. 2 and 4A). However, when A3-depleted
virus was used to infect A3-depleted cells, the difference in repli-
cation capacity wasmitigated to insignificant levels (Fig. 7B). This
implies that the replication advantage of HV-FIV Vif is exerted
FIG 5 APOBEC3 mRNA expression in feline cells. APOBEC3 mRNA levels
were determined by real-time qPCR for the Mya-1 feline T cell line, CrFK
feline cell line, and freshly isolated PBMC from four specific-pathogen-free
cats (n 4 replicates per cell type). Error bars represent standard errors of the
means.
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through enhanced anti-A3Z3 and anti-A3Z2-Z3 effects, or, con-
versely, that the relative growth disadvantage mapped to LV-FIV
Vif can be attributed to a relative inability to counteract the anti-
FIV effects of these cellular restriction enzymes—i.e., the differ-
ence in replication between HV-FIV vif- and LV-FIV vif-express-
ing viruses is dependent on feline A3Z3 and/or A3Z2-Z3.
DISCUSSION
Studies of FIV, SIV, and HIV have demonstrated that the patho-
genicity of the infecting lentiviral strain plays an important role in
determining the viral load and the severity of host immunodefi-
ciency (22, 24–26, 37, 43, 45). However, the specific viral charac-
teristics associated with pathogenicity remain relatively poorly
understood. FIV infection of the domestic cat offers a model sys-
tem for research on lentiviral pathogenesis in an authentic host
species with a disease pathology highly similar to that of HIV/
AIDS, since one of the best-characterized features of the FIV sys-
tem is the exhaustive documentation of strain-specific pathologies
associated with genetically divergent FIV strains (5, 17, 43–48).
Therefore, studies on the viral genetic basis for FIV pathogenicity
can inform our understanding of other lentiviruses, such as HIV,
by examining important genetic elements which lentiviruses
share, such as Vif. Likewise, elements that are unique to FIV, such
as OrfA, can be informative at a comparative level in understand-
ing lentiviral strategies for replication and evasion of host de-
fenses.
In this study, we examined the basis for FIV pathogenicity us-
ing vif and orfA accessory gene chimeras between two FIV molec-
ular clones with reproducibly and strikingly contrasting disease
potentials: HV-FIV (FIV-C36), which is highly virulent in vivo
and replicates rapidly in vitro; and LV-FIV (FIV-PPR), which is
less virulent in vivo and replicates more slowly and/or to lower
titers in vitro. We used overlapping PCR (82) to clone vif and orfA
accessory gene chimeras. The generation of such chimeras is fea-
sible in FIV but not in human or primate lentiviruses, which con-
tain overlapping transcription reading frames in accessory and
structural genes (Fig. 1) (94).
We generated 3 chimeric FIVs in which vif, orfA, or vif/orfA
fromHV-FIVwas substituted for these genes on the LV-FIV back-
bone, producing FIV-HVvif, FIV-HVorfA, and FIV-HVvif/orfA,
respectively. In all cell systems evaluated and by all measures of
viral replication, FIV-HVorfA displayed moderately increased
FIG 6 Knockdown of feline APOBEC3Z3 expression in CrFK-CD134 cells.
CrFK-CD134 cells were transiently transfected with siRNA targeting the feline
APOBEC3Z3 (A3Z3) mRNA or a nontargeting negative-control siRNA. Ex-
pression of A3Z3 (A), A3Z2-Z3 (B), and A3Z2 (C) mRNA was determined by
qPCR using gene-specific primers. The percentage of mRNA expression (n
4) was plotted relative to the level of expression in untransfected cells. The
expression of anti-FIV genes A3Z3 andA3Z2-Z3was decreased by85% for 7
days. The expression of A3Z2, thought to be inconsequential to FIV growth,
was not altered. Error bars represent standard errors of the means.
FIG 7 Vif-specific replication capacity is dependent on feline APOBEC3. (A) CrFK-CD134 cells expressing A3Z3 (control siRNA treated) were infectedwith FIV
produced in CrFK cells expressing A3Z3. (B) Cells depleted of A3Z3 (anti-A3Z3 siRNA treated) were infected with FIV produced in A3Z3-depleted CrFK cells.
LV-FIV and FIV-HVvif p26 levels in supernatants were normalized to HV-FIV p26 levels and are expressed as percentage of HV-FIV p26 antigen (Ag). Day 2
supernatants did not have detectable virus production (FIV p26) and, thus, are not shown. Error bars indicate standard errors of the means (ns, not significant;
P  0.05). Data shown are representative of three experiments with similar results. A significant difference in growth between LV-FIV and FIV-HVvif in the
presence of A3Z3 (A) that is not recapitulated in the absence of A3Z3 (B) demonstrates that APOBEC3 restriction is a significant component underlying the
decreased replicative capacity associated with vif from LV-FIV versus the replicative capacity associated with vif from HV-FIV.
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replication kinetics compared to the replication of the isogenic
parental LV-FIV, and chimeric viruses expressing HV-FIV vif or
vif/orfA had strongly increased replication kinetics compared to
the replication of LV-FIV, nearly equaling that of the virulent
parental FIV. This finding suggests that these nonstructural ele-
ments may play a significant role in the capacity for replication
and, thus, may be a mechanism for enhancing virulence.
In Mya-1 cells, the degree of viral replication for chimeric vi-
ruses (versus the replication of the parental LV-FIV, as measured
by p26 ELISA [Fig. 2] or RT activity [Fig. 3A]) appeared to be
relativelymore enhanced than the viralDNA load (asmeasured by
qPCR [Fig. 3B]). While the assays used cannot be directly com-
pared and the scales of comparison are different (linear for viral
production and log for proviral integration), this observation sug-
gests that high-virulence Vif and OrfA may have a greater en-
hancement of postintegration events (viral transcription, transla-
tion, assembly, and release) than of preintegration events. This
observation is consistent with a number of possible mechanisms,
including an enhanced ability to counteract deamination-depen-
dent inhibition by feline A3.
We further demonstrated that the enhancement of FIV-HVvif
replication is apparent only in the presence of feline A3 proteins,
suggesting that naturally occurring differences in lentiviral Vif
contribute to viral replication capacity and virulence via interac-
tion with host A3. The interaction between lentiviral Vif and host
A3 is a critical factor determining the species specificity of lentivi-
ruses. For instance, the inability of HIV-1 to infect species other
than humans and chimpanzees is based largely on the species-
specific adaptation of Vif to humanA3 proteins (72, 95–97). Like-
wise, we have found that challenge of domestic cats with the puma
strain of FIV (FIV-Pco) results in an initial productive infection
that diminishes to undetectable levels over time (98). The reduc-
tions in virus expression coincide with G-to-A hypermutation in
the provirus, consistent with the interpretation that FIV-PcoVif is
not well adapted to target domestic cat A3 (99).
While pathogenicity is likely related to numerous complex vi-
ral traits, the ability to counteract A3 intracellular restriction via a
more “robust” Vif may be an important virulence determinant.
Vif from one particular lentiviral species typically protects against
A3 proteins from its native host; i.e., FIV Vif mitigates feline A3
activity, HIV Vif mitigates human A3 activity, etc. Vif antagonism
of a matched-host A3 protein is not necessarily complete, how-
ever. A3 proteins can cause sublethal levels of G-to-A mutation
even in the presence of a functional Vif (100, 101), suggesting that
sufficient A3 evades Vif-mediated degradation to directly affect
virus evolution/divergence. Additionally, when transfected at
high levels, A3 proteins are able to overwhelm matched-host Vif,
resulting in a virus restriction phenotype compared to the pheno-
type seen with normal A3 expression (55, 59, 61, 62). In a clinical
setting, polymorphisms in human A3 genes have been associated
with the risk of HIV acquisition (102–104) and with HIV disease
progression (102, 105). Likewise, several reports have found that
higher levels of A3 expression are associated with lower HIV loads
(106, 107) and resistance to infection (108, 109). These studies
suggest that there is a dynamic balance between A3-mediated re-
striction and Vif-mediated protection that logically extends to a
role for lentiviral Vif with significant impact on viral replication
and pathogenicity. Indeed, it has been shown that the ability of
HIV Vif to neutralize A3 proteins in vitro can differ between HIV
subtypes (110, 111) or between strains of the same subtype (112).
While the studies cited above utilized in vitro single-replica-
tion-cycle assays to support these observations, differences in Vif
activity between naturally occurring lentiviral strains have not
been explored in depth, especially in the context of multicycle
whole-virus replication. Here, we examined fully replication-
competent vif gene chimeras constructed between two FIV strains
with well-characterized and divergent pathological consequences
that directly correlate with in vitro growth characteristics (47, 48).
These results suggest a model in which lentivirus-host adaptation
is a continuum that is highly dependent upon Vif and that natu-
rally occurring differences in lentiviral Vif can control the virus
replication that is associated with pathogenic potential. Explana-
tions for these findingsmight include strain-specific differences in
(i) vif transcription levels, (ii) Vif-induced degradation of A3, (iii)
Vif protein stability, or (iv) sequestration of A3 proteins which
does not result in degradation.
The finding that HV-FIVVif confers greater replication capac-
ity than LV-FIV Vif in a common viral backbone additionally
raises the question of what regions of Vif are essential for confer-
ring this phenotype. Comparison of the Vif amino acid sequences
of these two viruses shows 84% identity, with 40 amino acid dif-
ferences, 10 of which are considered amino acids with highly dis-
similar properties (see Fig. S2 in the supplemental material).
Amino acid changes occur in a putative Cullin5 zinc-coordinating
motif and immediately adjacent to a putative BC box (proposed
by Stern et al. [72]), both considered highly relevant functional
domains. Alternatively, sequence differences which affect the Vif
expression level or stability might be relevant.
Multiple potential functions have been ascribed to the small,
77-amino-acid FIV OrfA protein. Originally characterized as a
transactivator of viral protein expression (77), similar to HIV Tat,
the mechanism of action is distinct from those of other lentiviral
transactivators and the net upregulation of transcription is rela-
tively weak (73, 113). OrfA has also been shown to affect virion
formation and infectivity (73), as well as to localize to the nucleus
and induce G2 cell cycle arrest (78), similar to HIV Vpr. Most
recently, it has been demonstrated that OrfA downregulates the
surface expression but not the transcription or translation of the
primary FIV receptor CD134 and that OrfA-negative FIVs are
unable to productively infect CD134-expressing cells (80). OrfA
inhibition ofCD134may facilitatemore-efficient virus release due
to decreased receptor interactions with progeny virus, similar to
the effects attributed to HIV Vpu and Nef on CD4 (90). However,
another recent study suggests that this effect may be related to cell
type and, potentially, other virus-specific factors (89). Interest-
ingly, the orfA gene is the most genetically heterogeneous portion
of the FIV genome when compared across all known FIV isolates.
HV-FIV and LV-FIV OrfA proteins share only 65% amino acid
identity, with 27 total differences, of which 8 are highly dissimilar
amino acids (see Fig. S2 in the supplemental material). This high
level of diversity provides a potential basis for functional differ-
ences between strains.
We found that replacing the LV-FIV orfA with the HV-FIV
orfA resulted in a moderate increase in viral replication capacity.
The double accessory gene chimera FIV-HVvif/orfA displayed
replication kinetics similar to those of FIV-HVvif (Fig. 2, 3, and 4),
suggesting that the gain of function resulting from the high-viru-
lence orfA is weaker than that conferred by the high-virulence vif.
FIV OrfA-mediated downregulation of the FIV primary binding
receptor CD134 is associated with the ability of the virus to repli-
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cate in CD134-expressing cells (80). Thus, a possible mechanism
to explain the replication differences between strains could be that
increased CD134 downregulation might facilitate efficient virus
release and promote replication.We observed that CD134 surface
expression appeared to correlate inversely with the rate of virus
replication; i.e., lower expression of CD134 was associated with
more-rapid viral replication (Fig. 4). However, ascribing effects
on cellular protein expression to different viruses in a low-MOI,
multiple-replication-cycle experiment is likely to be confounded
by viruses replicating and spreading to new cells at different rates
due to potentially unrelated elements (such as Vif).
In this study, we chose to focus on a comparison of vif and orfA
chimeric and parental strain replication in T cells and PBMC,
since these are major targets of FIV infection and replication in
these cell types has been shown to correlate with replication in vivo
(47, 114). However, macrophages also play an important role in
establishing productive lentiviral infection, and both vif and orfA
are required for productive FIV infection of macrophages (49, 74,
76). Therefore, future work aimed at understanding the mecha-
nism of the observed differences in vif and orfA chimeric virus
replication may benefit from comparison of virus replication in
feline macrophages.
The results of this study identify an important mechanism for
lentiviral virulence in a model relevant for HIV/AIDS. While it is
well established that A3 plays a key role in restricting lentiviral
cross-species infection, these findings support the concept that
host cellular A3 can also affect the replication of host-adapted
lentiviral strains, resulting in a continuum of consequences from
aborted infection to significant virulence. The dynamic balance
between A3-driven host restriction and Vif-driven viral escape
from restriction is ongoing and may influence the ability of lenti-
viruses to cause progressive disease. This system will provide an
opportunity to study specific Vif-A3 interactions that are relevant
in vivo and determine the mechanism of increased Vif-dependent
lentiviral replication capacity, suggesting rational and novel mo-
dalities for additional lentiviral therapeutics. The chimeric system
outlined here will also provide a useful basis for more clearly de-
lineating the function of OrfA with respect to FIV replication and
virulence and for potentially identifying additional host restric-
tion factors relevant to limiting lentiviral pathogenicity.
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LV  AGACACGTAAAGAGAGTCCCAGAACCCTGCGCTCTTCCTGAAGGGGATGAGTGACGAAG 
HV  --G---A--CG-------------------A-----------------------A---- 




IN amino acids 
LV  ..R..H..V..K..R..V..P..E..P..C..A..L..P..E..G..D..E..* 
HV  ..-..-..I..R..-..-..-..-..-..-..T..-..-..-..-..-..-..* 









LV  GGAAAACTGTGAATGGAAG---TAATA 
HV  ---G-G--A----------AGA----T 









LV  ATAGATACTGCTTAGAAATATTTATAATAATATTTCATTTGCAACAATAATTATGGCAGAAGGGTTT 
HV  ---AG-T---------G------G-T-----T------C-A--T------A------------A--- 





pol stop A pol/vif junction 
B 
vif stop orfA start 
vif/orfA junction 
C orfA/rev junction 
rev start orfA stop 
D 
Figure S1.  Construction of vif/orfA chimeric viruses.  Junctions between LV-FIV and HV-FIV 
sequences resulting from overlapping PCR (A-C) are indicated by red lines.  LV-FIV derived sequences are 
highlighted in yellow and HV-FIV derived sequences are highlighted in green.  Restriction enzymes used to 
backclone chimeric PCR fragments into LV-FIV genome are indicated (D).  Chimeric sequence junctions 















Restriction enzymes used to backclone chimeric PCR fragments into LV-FIV 
A   Vif 
 
  1 MSEEDWQVSK GLFAVLQGGV HSAMLYISEL PEMEKEQYKK  HV-FIV 
  1 MSDEDWQVSR RLFAVLQGGV YNAMLYISRL PQDEREKYKK  LV-FIV 
    **:******: X********* :.******.* *:X*:*:*** 
 
 41 EFKKRLLDKE TGFIRRLRKA EGIKWSFHTR DYYMGYVKEL  HV-FIV 
 41 DFKKRLLDTE TGFIKRLRKA EGIKWSFHTR DYHVGYVREM  LV-FIV 
    :*******.* ****:***** ********** **::***:*: 
 
 81 VAGSSTPDSL RLYIYISNPL WHGKYRPGLK NFNKEWPFVN  HV-FIV 
 81 VAGPTTPHSL RLYVYISNPL WHSQYRPGLV NFNKEWPFVN  LV-FIV 
    ***X:**.** ***:****** **.:*****X ********** 
 
121 MWIKTGFMWD DIEKQKICVG GEISPGWGPG MVGIAIKAFS  HV-FIV 
121 LWIKTGFMWD DIEKQNICIG GEVSPGWGPG MIGIAIKAFS  LV-FIV 
    :********* *****:**:* **:******* *:******** 
 
161 CGERKIEATP VMIIREEIDP KKWCGDCWNL MCLRNSPPGT  HV-FIV 
161 CGERKIEATP VMIIRGEINP KKWCGDCWNL MCLRNSPPET  LV-FIV 
    ********** *****X**:* ********** ********X* 
 
201 LQRLAMLACG RKAKCWRGCC NQRFVSPYRT PADLEVIQYK  HV-FIV 
201 LQRLAMLACG VQAKSWRGCC NQRFVSPYRT PADLEVIQSK  LV-FIV 
    ********** X:**.***** ********** ********X* 
 
241 PGWNLLWLGEL                                  HV-FIV 
241 PGWCMLWRGKL                                  LV-FIV 
    ***X:**X*:* 
 
 
B   OrfA 
 
  1 MEEIIPLFNK ATDKLGQEAA IRLFVLAHQI ERDKFIRLLH  HV-FIV 
  1 ME-VIRIFNK VAERLDKEAA IRIFVLAHQL ERDKLIRLLQ  LV-FIV 
    **X:*X:*** .:::*X:*** **:******: ****:****: 
 
 41 LLIWRDRFKV PNPRGCLCWW CCKLYYWQLQ STLSISSA    HV-FIV 
 41 GLLWRLRFRK PKSKDCLCWF CCRLYYWQLQ STLSIDTA    LV-FIV 
    X*:**X**:X *:X:X****: **:******* *****.:* 
 
 
Figure S2.  Vif and OrfA amino acid sequence similarity between HV-FIV and LV-FIV.  
Amino acid differences are highlighted with gray boxes, a putative Cullin5 zinc-coordinating motif 
in Vif  is underlined once and a putative BC box in Vif is underlined twice (92).  Each pair of 
amino acids is classified as identical (*), strongly similar (:), weakly similar (.), or dissimilar (X) 
based on Clustal Omega sequence alignment output. 
Table S1.  Primer and siRNA oligonucleotide sequences 
 
Name  Sequence           Notes 
A(f) TGTTGCCTAAAGGACATTGG all chimeras 
F(r) TTTGGTATCTCCGGGTCTTG all chimeras 
B.1(r) GTTCTGGGACTCTCCTTACGTGTCTCCTAGG FIV-HVvif 
C.1(f) CCTAGGAGACACGTAAGGAGAGTCCCAGAAC FIV-HVvif 
D.1(r) CGTATTACTTCCATTCATAGCTCTCCTAACCATAGC FIV-HVvif 
E.1(f) GCTATGGTTAGGAGAGCTATGAATGGAAGTAATACG FIV-HVvif 
B.2(r) AATTATCTCTTCCATTCACAGTTTTCCTCG FIV-HVorfA 
C.2(f) CGAGGAAAACTGTGAATGGAAGAGATAATT FIV-HVorfA 
D.2(r) GCTGCAAACCCTTCTGCCATATTTATTGATGTAGATG FIV-HVorfA 
E.2(f) CATCTACATCAATAAATATGGCAGAAGGGTTTGCAGC FIV-HVorfA 
Vif/Orf-F1 TCAAAAAGATAAGAAATGGAAAGG vif/orfA seq. 
Vif/Orf-R1 GGCCCTTCTTCATTCATTTG vif/orfA seq. 
Int-F2 TGCCTCATAAACATGAAGCATTAG integrase seq. 
Int-R2 GTCACTCATCCCCTTCAGGA integrase seq. 
Z2g-F7 TGGGCGGAAACTCTGTTATC A3Z2 qPCR 
Z2g-R7 GGAAGCACTGTTCTGCATGG A3Z2 qPCR 
Z3g-F3 AGGAAAACCTACTTGTGCTACC A3Z3 qPCR 
Z3g-R3 CGAATCTCTGGGATGTGTCC A3Z3 qPCR 
Z2Z3-F3 GTGGACCACAAGGGAATGC A3Z2-Z3 qPCR 
Z2Z3-R3 GGAAGGGCCAGTCTCTTTTTC A3Z2-Z3 qPCR 
Z3-03 
siRNA 




Underlined regions indicate reverse complement sequences specific to HV-FIV. 
